Oral immunization with attenuated Salmonella Typhimurium as a carrier of DNA vaccine against infectious hematopoietic necrosis virus (IHNV) in rainbow trout (Oncorhynchus mykiss).

Infectious hematopoietic necrosis virus (IHNV) is a serious pathogen in the salmonid aquaculture industry and leads to economic losses in the world. This study aimed to develop a new oral DNA vaccine designed to protect rainbow trout against infection by IHNV. Fish were administered via the oral route by the attenuated Salmonella enterica serovar Typhimurium as a carrier of pcDNA3.1-IHNG (glycoprotein (G)) plasmid for 7 days and finally, fish were challenged by 10 pfu ml IHNV. The results revealed that the antigen gene was identified in different tissues of rainbow trout at 15-, 30-, and 45 days post-vaccination (dpv). Also, the recombinant vaccine elicited both an innate and specific immune response, resulting in a significant upregulation of the expression levels of ifn-1, mx-1, vig-1, igm, and igt. In addition, serum levels of neutralizing antibodies were observed to be elevated in the vaccinated fish, in contrast to the unvaccinated fish, following 30 dpv. Compared to trout that received empty S. Typhimurium, notable differences in cumulative percentage mortality were evident among the vaccinated fish. The relative percent survival (RPS) was recorded at 58.2 % for the group that received oral vaccine, while the group that received empty S. Typhimurium exhibited an RPS of 18.2 %. Therefore, our results showed that this bacterial vector can be a candidate carrier for pcDNA3.1-IHNG plasmid that may be employed to confer protection to rainbow trout against IHNV.